

**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-36. (Canceled)

37. (Currently amended) ~~The~~ An isolated polypeptide ~~of Claim 36~~ comprising SEQ ID NO:4, wherein said polypeptide binds at least one of human IL-13 and human IL-4.

38. (Currently amended) ~~The~~ An isolated polypeptide ~~of Claim 37~~ comprising a ~~derivative~~ part or fragment of SEQ ID NO:4.

39. (Previously presented) The isolated polypeptide of Claim 38 comprising amino acids 26 to 426 of SEQ ID NO:4.

40. (Previously presented) The isolated polypeptide of Claim 38 comprising amino acids 26 to 345 of SEQ ID NO:4.

41. (Currently amended) The isolated polypeptide of any one of Claims ~~36-40~~ 37-40 in soluble form.

42. (Currently amended) The isolated polypeptide of ~~Claims 36-37~~ claim 37 wherein said polypeptide is glycosylated.

43. (Currently amended) The isolated polypeptide of ~~Claims 36-37~~ claim 37 wherein said polypeptide is unglycosylated.

44. (Currently amended) The isolated polypeptide of Claims ~~36-40~~ 37-40 in recombinant form.

45. (Currently amended) The isolated polypeptide of ~~Claims 36-38~~ claim 37 in mature form.

46. (Canceled)

47. (Currently amended) A composition comprising the isolated polypeptide of Claim 37 and a pharmaceutically acceptable carrier.

48. (Currently amended) A composition comprising the isolated polypeptide of Claim 38 and a pharmaceutically acceptable carrier.

49. (Currently amended) A composition comprising the isolated polypeptide of Claim 39 and a pharmaceutically acceptable carrier.

50. (Currently amended) A composition comprising the isolated polypeptide of Claim 40 and a pharmaceutically acceptable carrier.

51. (Canceled)